United States securities and exchange commission logo

                              July 11, 2023

       Zheng Wei, Ph.D.
       Chief Executive Officer
       Connect Biopharma Holdings Limited
       12265 El Camino Real, Suite 350
       San Diego, CA 92130

                                                        Re: Connect Biopharma
Holdings Limited
                                                            Annual Report on
Form 20-F for the Fiscal Year Ended December 31, 2022
                                                            Filed April 11,
                                                            File No. 001-40212

       Dear Zheng Wei:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 20-F for Fiscal Year Ended December 31, 2022

       Part I
       Item 3. Key Information, page 4

   1.                                                   In future filings,
please disclose prominently at the outset of Part I that you are not a
                                                        Chinese operating
company but a Cayman Islands holding company with operations
                                                        conducted by your
subsidiaries. In addition, please provide early in the Key Information
                                                        section a diagram of
your corporate structure.
       Permissions, Approvals, Licenses and Permits Required from the PRC
Authorities for Our
       Operations..., page 7

   2.                                                   Please disclose each
permission or approval that you or your subsidiaries are required to
                                                        obtain from Chinese
authorities to operate your business and to offer securities to foreign
                                                        investors in future
 Zheng Wei, Ph.D.
FirstName  LastNameZheng  Wei, Ph.D.
Connect Biopharma  Holdings Limited
July       NameConnect Biopharma Holdings Limited
     11, 2023
July 11,
Page  2 2023 Page 2
FirstName LastName
Item 4. Information on the Company
General Information, page 76

3.       Please revise future filings to disclose if you have specific cash
management policies that
         dictate how funds are transferred through your organization and if
applicable, describe
         such policies and procedures.
Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections,
page 174

4.       We note your statement that you reviewed your register of members and
public filings
         made by your securityholders in connection with your required
submission under
         paragraph (a). Please supplementally describe any additional materials
that were reviewed
         and tell us whether you relied upon any legal opinions or third-party
certifications such as
         affidavits as the basis for your submission. In your response, please
provide a similarly
         detailed discussion of the materials reviewed and legal opinions or
         certifications relied upon in connection with the required disclosures
under paragraphs
         (b)(2) and (3).
5.       In order to clarify the scope of your review, please supplementally
describe the steps you
         have taken to confirm that none of the members of your board or the
boards of your
         consolidated foreign operating entities are officials of the Chinese
Communist Party. For
         instance, please tell us how the board members    current or prior
memberships on, or
         affiliations with, committees of the Chinese Communist Party factored
into your
         determination. In addition, please tell us whether you have relied
upon third party
         certifications such as affidavits as the basis for your disclosure.
6.       With respect to your disclosure pursuant to Item 16I(b)(5), we note
that you have included
         language that such disclosure is    to the extent known.    Please
supplementally confirm
         without qualification, if true, that your articles and the articles of
your consolidated
         foreign operating entities do not contain wording from any charter of
the Chinese
         Communist Party.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

        You may contact Ibolya Ignat at 202-551-3636 or Franklin Wyman at
202-551-3660 if
you have questions regarding comments on the financial statements and related
matters. Contact
Tyler Howes at 202-551-3370 or Jennifer Thompson at 202-551-3737 if you have
any questions
about comments related to your status as a Commission-Identified Issuer during
your most
recently completed fiscal year. Please contact Tyler Howes at 202-551-3370 or
Alan Campbell
at 202-551-4224 with any other questions.
 Zheng Wei, Ph.D.
Connect Biopharma Holdings Limited
July 11, 2023
Page 3
FirstName LastNameZheng Wei, Ph.D.
                                                  Division of Corporation
Comapany NameConnect Biopharma Holdings Limited
                                                  Office of Life Sciences
July 11, 2023 Page 3
cc:       Steven Chan
FirstName LastName